Axcan Canasa Launch Planned For April With 70 Reps
Executive Summary
Axcan is planning to launch its mesalamine suppository product Canasa in early April with a U.S. sales force of approximately 70 sales reps.
You may also be interested in...
FDA Evaluating Vaccine GMP Requirements To Assess Impact on Supply
FDA is re-evaluating its approach to good manufacturing practices, FDA Acting Commissioner Lester Crawford, PhD, suggested during a June 12 hearing on vaccine supply
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011